Spironolactone seems effective for female pattern hair loss

Spironolactone seems effective for female pattern hair loss

(HealthDay)—Spironolactone may be an effective treatment for female pattern hair loss (FPHL), especially among patients with signs of hyperandrogenism, according to a study published in the October issue of the Journal of the American Academy of Dermatology.

Shannon Famenini, from the University of California, Los Angeles, and colleagues examined the effectiveness of spironolactone therapy in women with FPHL in a involving 166 patients. A survey study was performed in 64 women to examine the severity of disease, history of thyroid disease, and presence or absence of acne or hirsutism. Use and evaluation of the effectiveness of spironolactone was also reported.

The researchers found that none of the 19 patients on spironolactone reported worse thinning in the retrospective study. In the survey study, of the 20 patients on spironolactone, 15 percent reported worse thinning, while 45 percent reported no change, and 30 percent reported mild improvement or increased thickness. There was no correlation between spironolactone response and being on an (P = 0.7); patients with acne or hirsutism had a significantly better response to spironolactone (P = 0.05). No link was seen between spironolactone dose and response in either study.

"Combining data from our studies, 74.3 percent of patients receiving spironolactone reported stabilization or improvement of their disease (n = 29/39)," the authors write.


Explore further

Blood test for patients on acne medication deemed unnecessary

More information: Abstract
Full Text

Copyright © 2015 HealthDay. All rights reserved.

Citation: Spironolactone seems effective for female pattern hair loss (2015, September 26) retrieved 7 December 2019 from https://medicalxpress.com/news/2015-09-spironolactone-effective-female-pattern-hair.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
14 shares

Feedback to editors

User comments